|
GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products Administration accepted for review the new drug application for the use of Nucala for patients with chronic obstructive pulmonary disease with an eosinophilic phenotype. ‘If approved, Nucala could be the first approved biologic with monthly dosing for patients with COPD,’ GSK highlighted. Nucala is currently approved for use in China across three interleukin-5 mediated conditions. IL-5 is a key cytokine in type 2 inflammation which is an underlying driver in many diseases, GSK said. Nucala is currently not approved for COPD in any country. GSK shares were down 1.2% to 1,421.00 pence each on Thursday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
